Hallway Conversation: Perampanel

Published Online: Tuesday, March 20, 2012
In this podcast, part of Epilepsy.com’s Hallway Conversations series, Joseph Sirven, MD, professor of neurology at Mayo Clinic Arizona and editor-in-chief of Epilepsy.com, interviews Gregory Krauss, MD, professor of neurology at Johns Hopkins Medical School, about the promising new antiepileptic drug (AED) perampanel.
Dr. Krauss explains that perampanel, the first drug in its class fully developed to treat epilepsy, targets the AMPA receptor, 1 of 3 receptors that help control neuronal excitability of the sort involved in seizure generation. He adds that the drug has a long half life of 70 hours, which means that it only has to be taken once a day. In addition, he notes that perampanel, which has not yet been approved by the FDA, has shown great promise in treating refractory epilepsy, although there have been some variations in trial results, particularly from centers where data may not have been accurately recorded.
To listen to the podcast, click here and scroll down to the October 24, 2011, episode.
Latest Articles
James Schiffer, RPh, associate at Allegaert Berger & Vogel LLC, discusses some tips for pharmacists who are facing a Drug Enforcement Administration audit.
Carlos Aquino, founder and president of PharmaDiversion LLC, talks about the importance of the Drug Enforcement Administration's (DEA) diversion website.
Having trouble getting your hands on FluMist?
Novartis is paying $390 million to settle charges that it paid kickbacks to pharmacies to encourage drug sales.
Latest Issues